Orlistat with drospirenone/ethinylestradiol tablets combo improves visceral fat in PCOS patients: Study
China: A combination of orlistat with drospirenone/ethinylestradiol tablets (DRSP/EE) is better than DRSP/EE-alone in reducing body weight, visceral fat area (VFA), and other parameters in overweight or obese patients with polycystic ovary syndrome (PCOS), says a recent study. The study appears in Gynecological Endocrinology. Xiangyan Ruan and colleagues from China conducted the study...
China: A combination of orlistat with drospirenone/ethinylestradiol tablets (DRSP/EE) is better than DRSP/EE-alone in reducing body weight, visceral fat area (VFA), and other parameters in overweight or obese patients with polycystic ovary syndrome (PCOS), says a recent study. The study appears in Gynecological Endocrinology.
Xiangyan Ruan and colleagues from China conducted the study with the objective to investigate the combined effect of orlistat with drospirenone/ethinylestradiol tablets on the visceral fat area versus DRSP/EE-alone in overweight or obese PCOS patients.
In the prospective, open-label, 1:2 paired 3-monthly study, the researchers recruited 90 PCOS patients [body mass index (BMI) ≥24kg/m2]. Inclusion was done during the per-protocol defined recruitment time and numbered according to the entry order: group-1: No.1-60, orlistat plus DRSP/EE; group-2: No.61-90, DRSP/EE-alone.
Both the groups were given the same comprehensive intervention with regard to individualized, standardized management and lifestyle monitoring such as diet and exercise. VFA was the primary study endpoint. Secondary endpoints include anthropometric indices, sex hormones, and glucolipid metabolism. Within- and between-group analyses were performed.
Key findings of the study include:
- VFA [cm2] in group-1 after treatment decreased significantly, and the between-group comparison was highly significant.
- Body weight, hip circumference (HC), BMI, body fat (BF), free testosterone (FT), and low-density lipoprotein-cholesterol (LDL-C) significantly decreased in both groups (within-group analysis); the decrease in group 1 was significantly greater than in group 2.
- Systolic and diastolic blood pressure (SBP/DBP) and fasting plasma glucose (FPG) in group-1 were significantly decreased, significantly more in group-1 than in group-2.
"Our study is the first to investigate the effect of orlistat combined with DRSP/EE in overweight or obese PCOS patients compared with using DRSP/EE-alone," wrote the authors.
"The combination of orlistat with DRSP/EE was better than using DRSP/EE-alone in reducing VFA, body weight, BP, FT, and FPG, which provides evidence for the choice of rational drug use in clinical practice," they concluded.
Min, Min, et al. "Effect of Orlistat During Individualized Comprehensive Life-style Intervention On Visceral Fat in Overweight or Obese PCOS Patients." Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology, 2022, pp. 1-5.
Medha, MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at firstname.lastname@example.org. Contact no. 011-43720751